Remus Pharmaceuticals Limited Revenue and Competitors
Estimated Revenue & Valuation
- Remus Pharmaceuticals Limited's estimated annual revenue is currently $11.7M per year.
- Remus Pharmaceuticals Limited's estimated revenue per employee is $201,000
Employee Data
- Remus Pharmaceuticals Limited has 58 Employees.
- Remus Pharmaceuticals Limited grew their employee count by 23% last year.
Remus Pharmaceuticals Limited's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Managing Director | Reveal Email/Phone |
3 | Regulatory Affairs Manager | Reveal Email/Phone |
4 | Executive | Reveal Email/Phone |
5 | Business Development & Operations (Executive) | Reveal Email/Phone |
6 | Business Development Executive | Reveal Email/Phone |
Remus Pharmaceuticals Limited Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $32.4M | 161 | 20% | N/A | N/A |
#2 | $16.3M | 81 | 7% | N/A | N/A |
#3 | $18.7M | 93 | 16% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $12.3M | 61 | 7% | N/A | N/A |
#6 | $184.1M | 916 | 38% | $50M | N/A |
#7 | $27.7M | 138 | 8% | N/A | N/A |
#8 | $112.4M | 559 | 8% | N/A | N/A |
#9 | $12.5M | 62 | 11% | N/A | N/A |
#10 | $8M | 40 | 14% | N/A | N/A |
What Is Remus Pharmaceuticals Limited?
Remus focuses on marketing, distributing and exporting top-of-the-line complex generics certified by regulatory authorities. Backed by expert scientists, we make “healing through medicines” globally affordable. For over a decade, Remus has been at the forefront of critical healthcare globally.
keywords:N/AN/A
Total Funding
58
Number of Employees
$11.7M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.6M | 58 | 7% | N/A |
#2 | $7.6M | 58 | N/A | N/A |
#3 | $11.5M | 58 | N/A | N/A |
#4 | $12.2M | 58 | 2% | N/A |
#5 | $6.3M | 58 | -9% | N/A |